New alpha radiation therapy shows promise for tough prostate cancer
NCT ID NCT07214961
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new radioactive drug called AB001 in 80 men with advanced prostate cancer that has stopped responding to hormone therapy. The drug delivers a powerful alpha radiation dose directly to cancer cells. The main goals are to check safety and find the best dose and schedule for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BAMF Health
Grand Rapids, Michigan, 49503, United States
-
United Theranostics
Princeton, New Jersey, 08540, United States
-
XCancer
Omaha, Nebraska, 68130, United States